Medline Industries, Inc.

medline.com

In a complex healthcare world, Medline strives to help our customers achieve both clinical and financial success. We do that through a personalized approach to listen and better understand our customers’ needs in an environment that tirelessly demands lower costs and better outcomes. We are both a manufacturer and distributor with 1,600 direct sales reps who are dedicated points of contact for customers across the continuum of care. Because of our capabilities and engagement with other clinical and industry thought leaders, we deliver the most robust product portfolio and patient-care solutions to help healthcare providers perform at their very best.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DIAGNOSTICS

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

news image

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More

MEDICAL

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

news image

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More

INDUSTRIAL IMPACT

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More
news image

DIAGNOSTICS

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More
news image

MEDICAL

DEBIOPHARM ANNOUNCES FIRST PATIENT DOSED IN INVESTIGATOR-INITIATED, RANDOMIZED PHASE II, OPEN-LABEL CLINICAL TRIAL FOR ITS ANTIVIRAL ALISPORIVIR

Debiopharm | January 18, 2021

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The e...

Read More
news image

INDUSTRIAL IMPACT

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More
news image

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More